These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

598 related articles for article (PubMed ID: 9782644)

  • 1. Sentinel surveillance shows small decline in MMR coverage.
    Commun Dis Rep CDR Wkly; 1998 Sep; 8(36):317, 320. PubMed ID: 9782644
    [No Abstract]   [Full Text] [Related]  

  • 2. MMR vaccine coverage at 24 months stabilises in the UK.
    Commun Dis Rep CDR Wkly; 1999 Mar; 9(13):113, 116. PubMed ID: 10230112
    [No Abstract]   [Full Text] [Related]  

  • 3. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

  • 4. [Vaccination rate for triple measles-rubella-mumps vaccine in Empoli Val d'Elsa area health district U.S.L. 11, Tuscany Region].
    Salvadori P
    Ann Ig; 1998; 10(1):19-24. PubMed ID: 9616974
    [No Abstract]   [Full Text] [Related]  

  • 5. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A second dose of MMR vaccine for children in the United Kingdom.
    Commun Dis Rep CDR Wkly; 1996 Jul; 6(30):259. PubMed ID: 8755703
    [No Abstract]   [Full Text] [Related]  

  • 7. MMR vaccine--one year on.
    Walker D
    Practitioner; 1990 May; 234(1489):550-2. PubMed ID: 2392406
    [No Abstract]   [Full Text] [Related]  

  • 8. The elimination of indigenous measles, mumps, and rubella from Finland by a 12-year, two-dose vaccination program.
    Peltola H; Heinonen OP; Valle M; Paunio M; Virtanen M; Karanko V; Cantell K
    N Engl J Med; 1994 Nov; 331(21):1397-402. PubMed ID: 7969278
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The measles-mumps-rubella vaccination program in Finland.
    Redd SC; Wharton M; Hadler SC; Orenstein WA
    N Engl J Med; 1995 Apr; 332(16):1102-3. PubMed ID: 7898540
    [No Abstract]   [Full Text] [Related]  

  • 10. [Conjugated vaccine against measles, rubella and mumps].
    Vopr Virusol; 1989; 34(1):117-9. PubMed ID: 2728403
    [No Abstract]   [Full Text] [Related]  

  • 11. [Certain problems with limits of immunity against measles, mumps and rubella].
    Magdzik W
    Przegl Epidemiol; 1993; 47(1-2):47-53. PubMed ID: 8351387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. From the Centers for Disease Control and Prevention. Measles--United States, 1996, and the interruption of indigenous transmission.
    JAMA; 1997 May; 277(17):1345-6. PubMed ID: 9134928
    [No Abstract]   [Full Text] [Related]  

  • 13. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of a local newspaper campaign on the uptake of the measles mumps and rubella vaccine.
    Mason BW; Donnelly PD
    J Epidemiol Community Health; 2000 Jun; 54(6):473-4. PubMed ID: 10818125
    [No Abstract]   [Full Text] [Related]  

  • 15. [Issues related to rubella, measles and epidemic parotiditis in the Russian Federation].
    Zverev VV; Iuminova NV
    Vopr Virusol; 2004; 49(3):8-11. PubMed ID: 15188648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic analysis of measles elimination program in the Republic of Korea, 2001: a cost benefit analysis study.
    Bae GR; Choe YJ; Go UY; Kim YI; Lee JK
    Vaccine; 2013 May; 31(24):2661-6. PubMed ID: 23602654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measles/mumps/rubella vaccine.
    Lancet; 1988 Oct; 2(8615):860. PubMed ID: 2902310
    [No Abstract]   [Full Text] [Related]  

  • 18. [Measles, mumps and rubella vaccination status of school beginners in Munich].
    Markuzzi A; Schlipköter U; Weitkunat R; Meyer G
    Soz Praventivmed; 1997; 42(3):133-43. PubMed ID: 9334085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Two doses of MMR vaccine--sufficient to eradicate measles, mumps and rubella?
    Fahlgren K
    Scand J Soc Med; 1988; 16(3):129-35. PubMed ID: 3057621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].
    Janaszek-Seydlitz W; Bucholc B; Wysokińska T; Górska P; Gniadek G
    Przegl Epidemiol; 2003; 57(2):281-8. PubMed ID: 12910596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.